FDA Commissioner Dr. Robert M. Califf joined the 2022 BIO International Convention for a fireside chat, in which he discussed his view on Accelerated Approval, what he considers the leading cause of death in America, and the legacy he hopes to leave behind.
On Accelerated Approval
“I’m a big fan of Accelerated Approval,”he told BIO President and CEO Dr. Michelle McMurry-Heath.
He explained that we need to think about it like a relay race: “FDA shouldn’t stop trying to be the fastest team and the most efficient team on the first lap.” Still, we shouldn’t “just drop the baton at the end of the first lap and hope [Centers for Medicare and Medicaid Services] can find the baton and get going.”
“Making sure those confirmatory studies get done is really the critical thing,” he said, responding to Dr. McMurry-Heath’s question about Accelerated Approval in the FDA user fee negotiations. “The public is watching closely.”
On Misinformation & Life Expectancy
“Misinformation is the leading cause of death in the United States today,” he said, noting that almost all COVID deaths now are preventable, if patients are up-to-date on vaccines.
He related it to the dismal life expectancy in the U.S., which is “not because of some mysterious problem but because of chronic common disease,” including heart disease, diabetes, and mental health. “For most of these things, we do have effective treatments already—they just need to be used better.”
On His Legacy
When asked what legacy he hopes to leave at FDA, after serving his second term, Dr. Califf responded: “leaving the FDA in a better position than it was in to optimize public health.”
He also discussed his views on evidence-generation, the role of technology in real-world data, and more—read the recap on Bio.News.
More Health Care News:
Bio.News: Panelists praise FDA’s cooperation on PDUFA
“Improvements proposed to the next iteration of the Prescription Drug User Fee Act (PDUFA) include an opportunity for developers of candidate drugs to hold more meetings with the FDA, an increase in staff that will build expertise at the FDA, a new rare disease program, and provisions to support diversity in clinical trials, according to a panel moderated by Khushboo Sharma, Chief of Staff and Senior Vice President at BIO. Potential problems with PDUFA VII include changes to the FDA’s Accelerated Approval pathway.”
Bio.News: Panel decries lack of attention for antimicrobial resistance
“We need to bring the passion that our community now has to tackle pandemics and bring it to AMR,” said Colonel (Ret.) Matthew Hepburn of DARPA. “I’m cautiously optimistic.”